This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mock, P. Articles by Bidart, J. M. Search for Related Content PubMed PubMed Citation Articles by Mock, P. Articles by Bidart, J. M.

Pro-EPIL Forms Are Present in Amniotic Fluid and Maternal Serum during Normal Pregnancy

Service de Gynécologie Obstétrique, Hôpital Antoine Béclère (P.M., R.F.), Clamart, Service de Biologie Oncologique (P.M., D.B., D.A.D., F.T., J.M.B.) Institut Gustave-Roussy, Villejuif, Laboratoire d’Immunologie des Tumeurs UPRESA 8067 CNRS (D.B., L.L., J.M.B.), Faculté des Sciences Pharmaceutiques et Biologiques de Paris, Université René Descartes, Paris, France; and Service de Gynécologie et d’Obstétrique (P.M.), Hôpitaux Universitaires de Genève, Suisse.

Address correspondence to: Jean-Michel Bidart, Department of Clinical Biology, Institut Gustave-Roussy, 39, rue Camille Desmoulins, Villejuif, France 94805.

Abstract

Recent observations based on immunohistochemistry and RT-PCR demonstrate that early placenta insulin-like peptide (EPIL), encoded by the INSL4 gene, is present in the placenta during gestation. In the present study, we report on the development of a specific immunoassay, entirely based on two monoclonal anti-peptide antibodies (mAbs), and its use for the detection of pro-EPIL forms in biological fluids during pregnancy. One mAb directed against the C-connecting peptide was used to capture pro-EPIL forms and their binding was revealed by a radiolabeled anti-A chain mAb as the indicator. A composite synthetic peptide, encompassing the C- and A-domains, was utilized as the standard. Under these experimental conditions, the assay displays a sensitivity limit of 2 ng/mL. Pro-EPIL molecular forms were detected in both amniotic fluid and maternal serum of pregnant women. At 12 to 16 weeks of pregnancy, the pro-EPIL level was higher in amniotic fluid (246 ± 50.8 ng/mL) than in maternal serum (5 ± 2.0 ng/mL). As gestation advanced, so the concentration of pro-EPIL forms decreased in amniotic fluid while its level increased in maternal serum. Interestingly, in amniotic fluid, the pattern of pro-EPIL concentration during pregnancy is very similar to that observed for human chorionic gonadotropin (hCG) and its free subunits. The pattern of serum pro-EPIL concentration is similar to that of the free -subunit. Together with our previous immunohistochemical observations, these results indicate that pro-EPIL is preferentially secreted by cytotrophoblasts in amniotic fluid and that the biosynthesis of hCG subunits and EPIL may be regulated by common pathways. Overall, our observations strongly suggest that EPIL may play a critical physiological role during embryonic and foetal development.

This article has been cited by other articles:

				B Brandt, D Kemming, J Packeisen, R Simon, M Helms, U Feldmann, A Matuschek, C Kersting, B Hinrichs, J-M Bidart, et al. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility Endocr. Relat. Cancer, December 1, 2005; 12(4): 823 - 837. [Abstract] [Full Text] [PDF]

				L. Millar, N. Streiner, L. Webster, S. Yamamoto, R. Okabe, T. Kawamata, J. Shimoda, E. Bullesbach, C. Schwabe, and G. Bryant-Greenwood Early Placental Insulin-Like Protein (INSL4 or EPIL) in Placental and Fetal Membrane Growth Biol Reprod, October 1, 2005; 73(4): 695 - 702. [Abstract] [Full Text] [PDF]

				B. Brandt, A. Roetger, J.-M. Bidart, J. Packeisen, K. Schier, J.-H. Mikesch, D. Kemming, W. Boecker, D. Yu, and H. Buerger Early Placenta Insulin-like Growth Factor (pro-EPIL) Is Overexpressed and Secreted by c-erbB-2-positive Cells with High Invasion Potential Cancer Res., February 1, 2002; 62(4): 1020 - 1024. [Abstract] [Full Text] [PDF]